10 reports of this reaction
1.7% of all CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE reports
#13 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #13 most commonly reported adverse reaction for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, manufactured by Bausch Health US, LLC. There are 10 FDA adverse event reports linking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE to APPLICATION SITE ERYTHEMA. This represents approximately 1.7% of all 579 adverse event reports for this drug.
Patients taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is a less commonly reported adverse event for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, but still significant enough to appear in the safety profile.
In addition to application site erythema, the following adverse reactions have been reported for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 10 FDA reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 1.7% of all adverse event reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, making it a notable side effect.
If you experience application site erythema while taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.